tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Kemp Dolliver, 7 are a BUY (70%), 3 are a HOLD (30%).
Analyst Kemp Dolliver, currently employed at BROOKLINE, carries an average stock price target met ratio of 26.67% that have a potential upside of 6.79% achieved within 28 days.
Kemp Dolliver’s has documented 18 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on VRCA, Verrica Pharmaceuticals at 01-Oct-2024.
Analyst best performing recommendations are on DARE (DARE BIOSCIENCE).
The best stock recommendation documented was for DARE (DARE BIOSCIENCE) at 9/5/2023. The price target of $5 was fulfilled within 51 days with a profit of $2.92 (36.87%) receiving and performance score of 7.23.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$25
$20 (400.00%)
$25
7 months ago
(12-Mar-2025)
6/9 (66.67%)
$15.45 (161.78%)
421
Buy
$1.25
$-5.56 (-81.64%)
2 years 9 months ago
(13-Jan-2023)
0/1 (0%)
$-3.28 (-72.41%)
What Year was the first public recommendation made by Kemp Dolliver?
